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Abstract
Background:  Hepatitis B virus (HBV) and HIV are endemic in Uganda. Co-infection is common and leads to rapid pro-
gression of  liver disease.  Burden of  co-infection is unknown yet most patients are on  lamivudine-only ART where  resist-
ance is frequent. Most patients are initiated on antiretroviral therapy (ART) without knowing their HBV status. 
Objectives:  To determine burden of  co-infection and HBV viral suppression among patients on ART in NorthernUganda. 
Methods: We recruited HIV infected adult patients on ART in a cross-sectional study.  Age, sex, ART regimen and dura-
tion were recorded. Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBcAb) and liver panel were per-
formed. For those HBsAg+, hepatitis B e antigen (HBeAg) and HBV DNA were performed.  CD4 cell count was recorded. 
Results: Three hundred patients were recruited. Twenty (6.7%) were co-infected, while 41% were anti-HBcAb+. Overall 
188 (62.7%) were on lamivudine- only HBV active drug.  Median ART duration 2 years (IQR 1-5),  mean CD4+ cell count 
317 cells/microlitre (SD 255-557).  Of   20 HIV/HBV co-infected, 11/20 (55%) were on lamivudine-only  ART, median 
duration 1.5 years. Nineteen (95%) had undetectable HBV DNA. Seventeen (85%) were HBeAg negative.   Mean  CD4+ 
cell count 327 cells/microlitre (SD 197-482). 
Conclusion: A large proportion of  patients were on lamivudine- only HBV-active ART.  Resistance may occur long term 
thus testing for HBV and correct ART is recommended   









Hepatitis B virus (HBV) infection is common in Ugan-
da with a national prevalence of  10% reported in 2009. 
However, the epidemiology varies considerably   in the 
different regions in Uganda . The Northern region has 
the highest prevalence of  between   20% to 25%.1  On 
the other hand human immune deficiency virus (HIV) 
is also endemic in Uganda with a national average of  
7.3%.The two viruses share modes of  transmission, 
thus co-infection is expected to be high. Previous stud-
ies in Uganda have reported co-infection rates of  10% 
to 23%.2,3
Human Immmune deficiency virus (HIV) infection is 
associated with rapid progression of  liver disease in 
persons who are co-infected with HBV.  This is even 
more relevant currently when antiretroviral therapy 
(ART) has improved life expectancy for patients with 
HIV even in resource limited settings. This situation 
has led to liver disease becoming one of  the most im-
portant causes of  early death among the HIV infected 
individuals in the Western world.4-6  Even where treat-
ment and monitoring is widely available, liver disease 
still accounts for up to 20% of  deaths in HIV positive 
patients.7  In the areas most affected by HBV and HIV 
infections,  high co-infection rates worsen the prognosis 
in dually infected individuals. Rates of  hepatitis B sero-
logical conversion and viral clearance have been shown 
to be lower in patients co-infected with HIV, leading to 
accelerated rates of  progression to cirrhosis.8
Lamivudine,   tenofovir and emtricitabine, used in HIV 
infection are as well effective against HBV.  Use of  
these drugs in the overall ART combination has led to 
significant improvement in outcome of  co-infected pa-
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tients. However, resistance to lamivudine (and emtric-
itabine) occurs very frequently. In co-infected patients 
the incidence of  resistance reaches up to 90% over 5 
years of  treatment.9 Resistance will lead to reversal of  
the gains achieved by using ART. All the complications 
that occur in co-infected patients who are not on ART 
will become tenable when lamivudine resistance occurs. 
Tenofovir however, has not shown significant resist-
ance over 5 years of  use in co-infected patients.10 An 
ART combination containing tenofovir+ lamivudine or 
tenofovir+ emtricitabine is recommended in co-infect-
ed patients.4,11,12 Such guidelines are not in existence in 
most sub-Saharan African countries despite the latter 
carrying the highest burden of  co-infections world-
wide. This could partly be because of  lack of  evidence 
of  resistance patterns. 
Unfortunately since most of  our patients are initiated 
on therapy without testing for HBV and majority have 
been on lamivudine monotherapy (for HBV in co-in-
fected patients) inadvertently there may be a lot of  re-
sistance in the patient population especially where the 
burden of  both infections is high. Hepatitis B viral loads 
and liver function tests may be indicators of  resistance 
and possible HBV flares. In this study we determined 
the burden of  co-infection and HBV viral suppression 
among patients who have already been on ART in the 
Northern part of  Uganda which carries a high burden 
of  HBV and HIV.  
Patients and methods
We conducted a cross-sectional study among patients 
attending the HIV clinic in Gulu regional referral hos-
pital.  At the time we started data collection this clinic, 
had 1,744 patients active on ART. Close to 200 clients 
attend the clinic everyday and most of  the patients were 
on ART combinations containing either zidovudine/
lamivudine or tenofovir/lamivudine in addition to nev-
irapine or efavirenz as first line combinations. A few 
patients were on alluvia with any of  the above combi-
nations for second line.  
All patients attending the clinic who where 18 years or 
more and on ART were eligible to participate in the 
study. They were recruited after signing informed con-
sent document. Because of  the large numbers, we re-
cruited the first 20 patients who fulfilled the eligibility 
criteria on each  clinic day as long as the participant had 
not been recruited before in this study.   
We collected data on age, sex, marital status, widow or 
widower as well as clinical information: history of  yel-
low eyes, family history of  liver diseases, ART regimen 
and duration on ART, any other drugs. We drew 10 mil-
liliters of  venous blood for further investigations, divid-
ed into purple top and red top containers, each carrying 
5 milliliters. We performed hepatitis B surface antigen 
(HBsAg) test using HBsAg card (Cypress Diagnostics, 
Langdorp, Belgium) using a drop of  whole blood. Re-
sults of  these tests were read in 20 minutes and report-
ed as positive or negative. The remaining samples  were 
then transported to the main laboratory where further 
testing was performed. For all patients, liver panel was 
performed using Eon one chemistry analyzer (Viral Di-
agnostics, Victoria, Australia), with reagents from Cy-
press Diagnostics (Langdorp, Belgium). The upper limit 
of  normal (ULN) for alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) was 40 IU/mL. 
On the other hand ULN for total Bilirubin, albumin, 
total protein, gamma glutamyl  transferase , and alkaline 
phosphatase (ALP) were reported as 17 micromol/L, 
50 g/L , 83 g/L , 54 U/L and 125 U/L  respective-
ly.  In addition, hepatitis B core antibody (HBcAb) was 
performed on all patients while  HBeAg testing was 
done  on samples that had initially tested positive for 
HBsAg.  The testing for HBcAb and HBeAg were done 
using Biomeriuex miniVidas automated immunoassay 
analyzer (Biomerieux, Marcy l’Etoile, France).  The 
same HBsAg positive samples were subjected to HBV 
DNA testing using real time polymerase chain reaction 
(RT PCR) using COBAS AmpliPrep/COBAS TaqMan 
HBV Test, v2.0 by Roche, with a lower limit of  quanti-
fication (LLOQ) of  20 IU/mL. Patients were requested 
to allow use of  their CD4 cell count results performed 
routinely in this clinic.
HBV viral loads was deemed to have been suppressed 
if  it was below the lower limit of  quantification of   20 
IU/mL.
The study was approved by School of  Medicine Re-
search Ethics committee of  Makerere University as 
well as the Uganda National Council for Science and 
Technology. 
Data was entered in a Microsoft access program and 
exported to stata- version 12  for analysis. The preva-
lence of  HBV infection was expressed as proportion 
of  those who tested HBsAg positive in the total pop-
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ulation recruited. Comparison of  liver panel among 
the co-infected and HIV mono-infected patients was 
performed at bivariate levels Variables with p-values of  
<0.05 were considered significant. 
Results
In the months of  May and June 2013, three hundred 
patients were recruited in the study, composed main-
ly of  young patients with a median age of  36.5 years, 
most of  whom (74.7) were of  female gender as seen 
in table 1. Twenty of  300 patients (6.7%) tested pos-
itive for HBsAg while 41% were exposed to hepatitis 
B (anti-HBcAb positive).  All patients were on ART 
of  whom 188 (62.7%) were on lamivudine as the only 
drug active on HBV in the ART combination and 110 
(36.7%) were on a combination of  lamivudine plus ten-
ofovir. Overall, patients had been on ART for a median 
duration of  2 years (IQR 1-5) and their mean CD4+ 
cell count was 317 cells/ µL (SD 197-482).
Table 1. Baseline characteristics of HIV infected patients on ART attending Gulu 
Regional referral hospital Infectious Diseases Clinic, 2013 (N=300) 
Parameters  
Age; years (median) 36.5 (10.6) 
Gender; Female n (%) 224 (74.7) 
ART regimen distribution*  
Lamivudine (%) 
Tenofovir (%) 
Lamivudine+Tenofovir, n (%) 
Tenofovir +Emtricitabine (TruvadaTM), n (%) 
 
188 (62.7) 
2  (0.6) 
110 (36.7) 
0 (0)) 
Duration on ART median(IQR) years  2 (1 - 5) 
CD4 count (mean)   cells/ µL 317 (197-482) 
HBsAg +, n (%) 20 (6.7) 
HBcAb, n (%) 118 (41.0) 
*This lists only drugs active against HBV in the ART regimen. Patients were on complete 
ART combinations 
Table 2 describes demographic, clinical and laboratory 
characteristics of  the 20 patients who were co-infected 
with HBV. Most of  these patients, 11/20 (55%) were 
on lamivudine only ART and they had been on ART 
for a median duration of  1.5 years. Nineteen (95%) of  
these patients had undetectable HBV viral loads over 
this median duration of  treatment.  Seventeen (85%) 
patients had the hepatitis B e antigen negative chronic 
HBV type. In general,  the mean CD4+ cell count of  
the 20 patients was 327 cells/ µL (SD 255-557) and liver 
enzymes (ALT, AST) were within normal limits. 
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Table 2 Demographic, clinical and laboratory characteristics of HBV HIV infected 
patients attending the Gulu HIV clinic 2013, (N=20)  
Parameters No Percent 
Age; median (IQR) 30.5 (27.5- 39)  
Gender; Female 19  95 















Median duration on ART,  years (IQR)  1.5 (0.75-5.0)  
Mean CD4 cell count/ µL (SD)  327 (255-557)  
HBeAg negative 17  (85.0)  
HBV DNA detected  1 5 
Mean ALT, U/L (SD)  26.3 (20.6)  
Mean AST, U/L (SD) 28.0 (12.9)  
*This lists only drugs active against HBV in the ART regimen. Patients were on complete 
ART combinations 
Comparing liver panel between HBsAg-positive and 
HBsAg-negative revealed no statistical difference in the 
two arms, except for a trend to higher total Bilirubin in 
the HBsAg negative individuals and this is shown on 
Table 3.  
Table 3. Comparison of liver panel among HIV infected patients with (HBsAg+) and 
without (HBsAg-) Hepatitis B infection in Gulu HIV clinic, 2013 
Variable HBsAg- HBsAg+ P-value 
Albumin: mean(SD), g/l  42 (0.46) 43 (4.1) 0.4419 
ALP: median (IQR), U/L  83 (68-99) 92 (76-109) 0.2015 
GGT: median (IQR), U/L 33 (24-56) 45 (29-84) 0.1265 
Bilirubin: mean (SD)   µL 85.0 (56.1) 57.8 (18.7) 0.0560 
Protein: mean (SD)    g/L 74 (0.81) 73 (7.3) 0.7404 
CD4 cell count: median (IQR) /µL  316 (190-481) 327 (255-557) 0.2945 
 
Discussion
Our study has demonstrated that most patients in this 
clinic have been on lamivudine  as the only active drug 
against hepatitis B in HIV infected patients. This has 
been the trend previously in most clinics in sub-Saha-
ran Africa where most ART combinations were com-
posed either of  zidovudine plus lamivudine, or stavu-
dine and lamivudine in addition to either nevirapine 
or efavirenz.13-15 In most patients these treatment regi-
mens were taken without routine screening for hepatitis 
B and most regimens did not therefore take HBV into 
consideration.
In this study we have shown that chronic hepatitis B oc-
curred in 6.7% of  the patients with a level of  exposure 
measured at 41%. These figures are lower than what has 
been shown in the general population in this Northern 
Ugandan region. Bwogi et al, in a study conducted as 
part of  National sero-survey in the year 2004 in Uganda 
demonstrated a general population prevalence of  21% 
in the North Central districts of  Uganda where Gulu is 
located.1 Another study conducted in 2009 by Ochola 
et al in Gulu Municipality in 2009 showed a prevalence 
of  17% in the Municipality.16  It is not clear whether 
this is a result of  general awareness of  the population 
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on HBV and the fact that many people have resorted 
to HBV vaccination in addition to the early childhood 
vaccination which was initiated in Uganda in 2002. 
Despite the 6.7% prevalence of  HBV and the fact that 
most patients were on lamivudine as the only drug ac-
tive against HBV in the ART combination we have 
shown that 93.7% had undetectable viral loads  over 
an average treatment period of  1.5 years. However one 
patient had detectable viral loads. This was a female 
patient who was HBeAg negative and had HBV viral 
loads of   2,464,000 IU/mL at nine years of  lamivu-
dine plus zidovudine combination.  The liver enzymes 
were actually elevated with an ALT level of  95.9 U/L. 
These findings show that lamivudine-only ART thera-
py  was adequate in suppressing HBV virus in the short 
run. As treatment duration increases there is likely to 
be an increasing number of  patients presenting with in-
creased viral loads as has been seen in the one patient 
described above. Although in this study resistance test-
ing was not done, it is likely that this patient already had 
breakthrough infection with HBV resistance and this 
could lead to worsening of  liver disease. In this patient 
the elevation of  the liver enzymes noted in the study 
already shows liver cell injury which if  not treated ad-
equately would lead to cirrhosis and its complications. 
We recommended HIV viral loads be performed for 
this patient and the treatment be changed to include 
tenofovir. . 
Limitations
This study had several limitations. First, because of  the 
cross-sectional nature of  the study we could not tell 
what the HBV viral loads were at initiation of  ART. The 
low HBV viral loads observed in these patients especial-
ly in those on lamivudine-only ART could be a result of  
low viral loads at initiation. Lamivudine is able to cause 
significant viral suppression in situation of  low viral 
loads at antiviral therapy initiation with limited chance 
of  accumulation of  resistance strains.1 The possibility 
of  low viral loads at initiation could also be entertained 
by the fact that most patients were HBeAg negative. We 
cannot however also tell if  the observed HBeAg status 
was a result of  seroconversion. This is however unlike-
ly since sero-conversion is not a common occurrence 
especially considering the average duration of  therapy 
and the fact that this HBV is occurring in combination 
with HIV.4,17,18 Also, a previous study   in the same lo-
cation in Northern Uganda showed  that even in the 
general population most patients are infected with the 
HBeAg negative HBV with low viral loads.16 Secondly, 
we were not able to perform sequencing thus making 
it difficult to know if  the high HBV viral loads seen in 
the one patient were a result viral mutations. In the HIV 
infected populations resistance rates to lamivudine of  
up to 90% has been shown by 5 years of  treatment.9 
It is possible that as more patients continue to be on 
the treatment with lamivudine-only ART more patients 
may be seen with HBV high viral loads. Thirdly, we did 
not assess adherence in the patients and were not able 
to perform HIV viral load testing. Suppression of  both 
HIV and HBV viral loads would have helped to define 
possibility of  good adherence.  It is important to note 
that the number of  patients on ART containing tenofo-
vir seem to be high in the later years and this could re-
duce the risk of  resistance and virologic breakthroughs 
since it is a very effective drug with limited resistance.4,10
Finally, there was no statistical difference in the liver 
enzymes among those who were HBsAg positive and 
those who were HBV uninfected. This could also mean 
that within the mean duration studied, the HBV sup-
pression was adequate.  
Conclusion 
The prevalence of  co-infection was 6.7% and most of  
these patients were on lamivudine- only antiretroviral 
therapy combination.  Although most patients were 
suppressed within a short duration of  treatment,  pro-
longed treatment with lamivudine could lead to resur-
facing of  HBV which could lead to worsening of  liver 
disease progression and outcome  as seen in the one 
patient. Treatment with tenofovir in combination with 
either lamivudine or emtricitabine is recommended to 
avoid this outcome   
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